β-hydroxy-β-methylbutyrate (HMB)
Phase 1
β-hydroxy-β-methylbutyrate (HMB) is one of 7 therapeutic programs targeting Amyotrophic Lateral Sclerosis (ALS). It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
12 competitors in Amyotrophic Lateral Sclerosis (ALS)
#DrugCompanyPhaseTrials
1Rilutek
AAzurity Pharmaceuticals
Phase 2
VHB937
NovartisPhase 2
Cromolyn Sodium
UUniversity of California, San Francisco
Phase 2
β-hydroxy-β-methylbutyrate (HMB)
DDuke University
Phase 1
XT-150
XXalud Therapeutics, Inc.
Phase 1
NUZ-001
MMerit E. Cudkowicz, MD
Preclinical
MTP-101C
UUniversity of Minnesota
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- DDuke University